Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Advance Nanotech Senior VP to lead biopharma seminar

Advance Nanotech Senior VP to lead biopharma seminar at University of Massachusetts Boston

New York City | Posted on April 25, 2006

Advance Nanotech, Inc., (OTC BB:AVNA.OB - News), the premier provider of financing and support services to expedite the commercialization of nanotechnology discoveries, today announced that Dr. Michael Helmus, senior vice president, BioPharma, will lead a seminar on Monday, April 24 on Commercializing Nanotechnology in BioPharma Applications. The seminar is sponsored by the Biology and Chemistry Departments of the University of Massachusetts, and will take place at the University’s Boston campus.

Who – Dr. Michael Helmus, senior vice president, BioPharma at Advance Nanotech will lead a seminar on Commercializing Nanotechnology in BioPharma Applications. Dr. Helmus currently serves on the University of Massachusetts Boston Science Advisory Board.

What – Spring 2006 Biology Seminar Series.

When – Monday, April 24 at 2:30 pm.

Where – University of Massachusetts, Boston Campus, Science Building, Small Science Auditorium, First Floor, Room S/1/006.

Why – The seminar will explore progress in the uses of nanotechnology in BioPharma Applications.

For more information on the seminar or to schedule a press briefing with Helmus, please contact Derek Brookmeyer at 415.623.2076. For more information about the seminar series, go to www.bio.umb.edu/events.

About Michael Helmus, Ph.D.
Dr. Helmus assumed the position of senior vice president, BioPharma at Advance Nanotech in August 2005. Dr. Helmus is responsible for managing all of the firm’s partnerships and investments related to the biopharma and life sciences fields. Before joining Advance Nanotech Dr. Helmus served as the Vice President, Advanced Biomaterials at Boston Scientific. Prior to that Dr. Helmus held research and development positions with organizations including Edwards Lifesciences, Baxter CVS, Pfizer, and Arthur D. Little. Dr. Helmus holds a PhD and an MS in Biomedical Engineering from Case Western Reserve University and a BS in Metallurgy and Materials Science from Lehigh University. Dr. Helmus’ expertise includes the identification and acquisition of new technologies, implementation and management of research and development programs, and intellectual property development and management. In the course of his career Dr. Helmus has been issued 26 U.S. patents, authored 47 technical publications and written 29 technology and market assessments.

####

About Advance Nanotech:
Advance Nanotech is dedicated to the successful commercialization of disruptive nanotechnologies to produce nano-enabled products. Advance provides financing and support services including commercialization guidance, project and infrastructure management, leadership assets, and counsel on intellectual property, licensing and regulatory issues to ensure maximum market potential. Advance Nanotech's diversified portfolio of 26 nanotechnologies, of which the company holds a majority stake in 21, impacts a range of applications including, but not limited to, sensors, medical therapeutics and composites. Advance is forging partnerships with leading manufacturers and universities in Europe, Asia and North America to transform innovative nanotechnology concepts into practical solutions.

For more information, please click here.

This document contains forward-looking statements by Advance Nanotech regarding its expectations as to its business, and involves risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those addressed in the forward-looking statements.

Factors that may cause such a difference include, but are not limited to, problems and risks associated with developments in the nanotechnology industry in general and in Advance Nanotech's products under development in particular; the potential failure of Advance Nanotech's products under development to prove safe and effective in application; uncertainties inherent in the early stage of Advance Nanotech's products under development; failure to successfully implement or complete research programmes; failure to receive marketing clearance from regulatory agencies for our products under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Advance Nanotech's business, structure or projections; the development of competing products; uncertainties related to Advance Nanotech 's dependence on third parties and partners; and those risks described Advance Nanotech 's filings with the SEC. Advance Nanotech disclaims any obligation to update these forward-looking statements.

Further information about these and other relevant risks and uncertainties may be found in the Advance Nanotech's findings with the Securities and Exchange Commission, all of which are available from the Commission as well as other sources.


Contact:
Derek Brookmeyer
Racepoint Group
One Embarcadero Center, Suite 500
San Francisco, CA 94111
P: 415.623.2076
F: 415.623.2087
dbrookmeyer@racepointgroup.com
www.racepointgroup.com

Copyright © Advance Nanotech

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Efficiency of Nanodrug Containing Antibiotics in Treatment of Infectious Diseases Evaluated August 31st, 2015

Researchers use DNA 'clews' to shuttle CRISPR-Cas9 gene-editing tool into cells August 30th, 2015

Iranian Scientists Use Artemisia Annua Plant to Produce Breast Cancer Drugs August 29th, 2015

Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015

Announcements

Nanotech could rid cattle of ticks, with less collateral damage September 1st, 2015

Scientists 'squeeze' light one particle at a time: A team of scientists have measured a bizarre effect in quantum physics, in which individual particles of light are said to have been 'squeezed' -- an achievement which at least one textbook had written off as hopeless September 1st, 2015

An engineered surface unsticks sticky water droplets August 31st, 2015

New material science research may advance tech tools August 31st, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic